.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cipla
Harvard Business School
Express Scripts
AstraZeneca
Chinese Patent Office
Mallinckrodt
Cerilliant
Fish and Richardson
US Army

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,637,540

« Back to Dashboard

Which drugs does patent 8,637,540 protect, and when does it expire?


Patent 8,637,540 protects OXAYDO and is included in one NDA.

This patent has thirteen patent family members in six countries.

Summary for Patent: 8,637,540

Title:Compositions for deterring abuse of opioid containing dosage forms
Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
Inventor(s): Kumar; Vijai (Morris Plains, NJ), Dixon; David (Woodside, NY), Tewari; Divya (West Chester, PA), Wadgaonkar; Dilip B. (Suffern, NY)
Assignee: Acura Pharmaceuticals (Chicago, IL)
Application Number:13/926,206
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► SubscribeY► Subscribe
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-002Jun 17, 2011RXNoNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,637,540

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,822,489Abuse deterrent compositions and methods of making same► Subscribe
7,201,920Methods and compositions for deterring abuse of opioid containing dosage forms► Subscribe
9,492,443Abuse deterrent compositions and methods of making same► Subscribe
8,409,616Extended release opioid abuse deterrent compositions and methods of making same► Subscribe
7,981,439Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof► Subscribe
8,101,630Extended release opioid abuse deterrent compositions and methods of making same► Subscribe
7,510,726Methods and compositions for deterring abuse of opioid containing dosage forms► Subscribe
7,476,402Methods and compositions for deterring abuse of opioid containing dosage forms► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,637,540

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel221018► Subscribe
Israel175863► Subscribe
Spain2637338► Subscribe
European Patent Office2420225► Subscribe
European Patent Office2402004► Subscribe
European Patent Office1694260► Subscribe
Canada2547334► Subscribe
Australia2017239544► Subscribe
Australia2015264950► Subscribe
Australia2013206525► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKinsey
Covington
Baxter
Fuji
UBS
Cantor Fitzgerald
Dow
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot